Alphamab Oncology announced that, with effect from March 15, 2021, Dr. Johannes NIPPGEN ('Dr. Nippgen') has been appointed as its chief medical officer, who will be primarily responsible for the clinical development and transitional research of the Company's innovative product pipelines, as well as participate in designing research and development strategy of innovative products and promote international cooperation. Dr. Nippgen has over 25 years of experience in medical industry. His industry expertise covers the clinical research and development and as well as project management in various international biopharma and biotech companies. From 2018 to 2021, he served as head of research and development in China at Merck Group.